Clinical Trial Update: Safety and Immunogenicity of Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01 Vaccines, Transmission Blocking Vaccines Against Plasmodium Falciparum, at Full and Fractional Dosing in Adults in Mali [Phase 1]

View source ↗

Summary

This Phase 1 trial assessed safety and immunogenicity of two malaria transmission-blocking vaccines, Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01, given at full and f…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria

Drugs mentioned

• Pfs230D1M-EPA/AS01
• Pfs25M-EPA/AS01

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Malaria | Phase 1 | Status: COMPLETED | Results posted: 2022-01-28